Condition
High-grade Ta/ T1 Papillary Disease Bladder Cancer
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Ndodecylbdmaltoside
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 3 (1)
Trial Status
Recruiting1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT04452591Phase 3Active Not Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT07283835Phase 2Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Showing all 2 trials
Research Network
Common Treatments
- Ndodecylbdmaltoside2
- Cretostimogene Grenadenorepvec2
Active Sponsors
- Lepu Biopharma Co., Ltd.1
- CG Oncology, Inc.1
Top Investigators
Fudan University
Related Conditions
- Non Muscle Invasive Bladder Cancer2